Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: Proposals for a revised grading system and consensus management guidelines

Annals of Oncology

Volumn 22, Issue 10, 2011, Pages 2191-2200

  Bernier, J ^a   Russi, E G ^b   Homey, B ^c   Merlano, M C ^b   Mesia R ^d   Peyrade, F ^e   Budach, W ^c  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b S CROCE E CARLE HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Cetuximab; Guidelines; Locally advanced squamous cell carcinoma of the head and neck; Management; Radiation dermatitis; Radiotherapy

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CELL SURVIVAL; DESQUAMATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HEAD AND NECK CARCINOMA; HUMAN; INNATE IMMUNITY; KERATINOCYTE; MULTIPLE CYCLE TREATMENT; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RADIATION ONCOLOGY; RADIODERMATITIS; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 80053159119     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr139     Document Type: Article

References (38)

1. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamouscell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
2. Gregoire V, Lefebvre JL, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5): v184-v186.
3. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-28.
4. Berger B, Belka C. Severe skin reaction secondary to concomitant radiotherapy plus cetuximab. Radiat Oncol 2008; 3: 5.
5. Budach W, Bolke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 2007; 357: 514-515.
6. Giro C, Berger B, Bolke E et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol 2009; 90: 166-171.
7. Mydin AR, Armstrong JG. Acneiform rash secondary to cetuximab plus head and neck radiotherapy [Letter]. Radiother Oncol 2007; 85: 171.
8. Bolke E, Gerber PA, Lammering G et al. Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther Onkol 2008; 184: 105-110.
9. Merlano M, Russi E, Benasso M et al. Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study. Ann Oncol 2011; 22: 712-717.
10. Calais G, Alfonsi M, Bardet E et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91: 2081-2086.
11. Wendt TG, Grabenbauer GG, Rodel CM et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998; 16: 1318-1324.
12. Teoh DC, Rodger S, Say J, Hartley A. Hypofractionated radiotherapy plus cetuximab in locally advanced head and neck cancer. Clin Oncol (R Coll Radiol) 2008; 20: 717.
13. Bernier J, Bonner J, Vermorken JB et al. Consensus guidelines for the management of radiation dermatitis and co-existing acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008; 19: 142-149.
14. US Department of Health and Human Services. National Institutes of Health. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). 28 May 2009 (v4.03: 14 June 2010). http://evs.nci.nih.gov/ftp1/CTCAE/About.html (October 2010, date last accessed).
15. Madison KC. Barrier function of the skin: "la raison d'etre" of the epidermis. J Invest Dermatol 2003; 121: 231-241.
16. Pastore S, Mascia F, Mariani V, Girolomoni G. The epidermal growth factor receptor system in skin repair and inflammation. J Invest Dermatol 2008; 128: 1365-1374.
17. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-1433.
18. Mascia F, Cataisson C, Lee TC et al. EGFR regulates the expression of keratinocyte-derived granulocyte/macrophage colony-stimulating factor in vitro and in vivo. J Invest Dermatol 2010; 130: 682-693.
19. Pastore S, Mascia F, Mariotti F et al. ERK1/2 regulates epidermal chemokine expression and skin inflammation. J Immunol 2005; 174: 5047-5056.
20. Sørensen OE, Thapa DR, Roupe KM et al. Injury-induced innate immune response in human skin mediated by transactivation of the epidermal growth factor receptor. J Clin Invest 2006; 116: 1878-1885.
21. Albanell J, Rojo F, Averbuch S et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20: 110-124.
22. Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 2001; 49: 427-433.
23. McQuestion M. Evidence-based skin care management in radiation therapy. Semin Oncol Nurs 2006; 22: 163-173.
24. Bone RC. Systemic Inflammatory Response Syndrome: A Unifying Concept of Systemic Inflammation. Philadelphia, PA: Lippincott 1997.
25. Heggie S, Bryant GP, Tripcony L et al. A phase III study on the efficacy of topical aloe vera gel on irradiated breast tissue. Cancer Nurs 2002; 25: 442-451.
26. Olsen DL, Raub W Jr, Bradley C et al. The effect of aloe vera gel/mild soap versus mild soap alone in preventing skin reactions in patients undergoing radiation therapy. Oncol Nurs Forum 2001; 28: 543-547.
27. Russi EG, Merlano MC, Comino A, Numico G. Ultrathin hydrocolloid dressing in skin damaged from alternating radiotherapy and chemotherapy plus cetuximab in advanced head and neck cancer (G.O.N.O. AlteRCC Italian Trial): in regard to Macmillan et al. (Int J Radiat Oncol Biol Phys 2007;68:864-872). Int J Radiat Oncol Biol Phys 2007; 69: 638-639.
28. Burch SE, Parker SA, Vann AM, Arazie JC. Measurement of 6-MV X-ray surface dose when topical agents are applied prior to external beam irradiation. Int J Radiat Oncol Biol Phys 1997; 38: 447-451.
29. Løkkevik E, Skovlund E, Reitan JB et al. Skin treatment with bepanthen cream versus no cream during radiotherapy-a randomized controlled trial. Acta Oncol 1996; 35: 1021-1026.
30. Schmuth M, Wimmer MA, Hofer S et al. Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study. Br J Dermatol 2002; 146: 983-991.
31. Li T, Perez-Soler R. Skin toxicity associated with epidermal growth factor receptor inhibitors. Target Oncol 2009; 4: 107-119.
32. Elliott EA, Wright JR, Swann RS et al. Phase III trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Trial 99-13. J Clin Oncol 2006; 24: 2092-2097.
33. Halperin EC, Gaspar L, George S et al. A double-blind, randomized, prospective trial to evaluate topical vitamin C solution for the prevention of radiation dermatitis. CNS Cancer Consortium. Int J Radiat Oncol Biol Phys 1993; 26: 413-416.
34. Pardo Masferrer J, Murcia Mejia M, Vidal Fernandez M et al. Prophylaxis with a cream containing urea reduces the incidence and severity of radio-induced dermatitis. Clin Transl Oncol 2010; 12: 43-48.
35. Pommier P, Gomez F, Sunyach MP et al. Phase III randomized trial of Calendula officinalis compared with trolamine for the prevention of acute dermatitis during irradiation for breast cancer. J Clin Oncol 2004; 22: 1447-1453.
36. Potera ME, Lookingbill DP, Stryker JA. Prophylaxis of radiation dermatitis with a topical cortisone cream. Radiology 1982; 143: 775-777.
37. Williams MS, Burk M, Loprinzi CL et al. Phase III double-blind evaluation of an aloe vera gel as a prophylactic agent for radiation-induced skin toxicity. Int J Radiat Oncol Biol Phys 1996; 36: 345-349.
38. Buiret G, Combe C, Favrel V et al. A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2010; 77: 430-437.